Neurocrine Biosciences Inc (NBIX)
125.00
+1.71
(+1.39%)
USD |
NASDAQ |
Nov 21, 16:00
123.15
-1.85
(-1.48%)
After-Hours: 20:00
Neurocrine Biosciences Revenue (Quarterly): 622.10M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 622.10M |
| June 30, 2024 | 590.20M |
| March 31, 2024 | 515.30M |
| December 31, 2023 | 515.20M |
| September 30, 2023 | 498.80M |
| June 30, 2023 | 452.70M |
| March 31, 2023 | 420.40M |
| December 31, 2022 | 412.00M |
| September 30, 2022 | 387.90M |
| June 30, 2022 | 378.20M |
| March 31, 2022 | 310.60M |
| December 31, 2021 | 312.00M |
| September 30, 2021 | 296.00M |
| June 30, 2021 | 288.90M |
| March 31, 2021 | 236.60M |
| December 31, 2020 | 247.90M |
| September 30, 2020 | 258.50M |
| June 30, 2020 | 302.40M |
| March 31, 2020 | 237.10M |
| December 31, 2019 | 244.10M |
| September 30, 2019 | 222.10M |
| June 30, 2019 | 183.50M |
| March 31, 2019 | 138.40M |
| December 31, 2018 | 131.45M |
| September 30, 2018 | 151.76M |
| Date | Value |
|---|---|
| June 30, 2018 | 96.90M |
| March 31, 2018 | 71.09M |
| December 31, 2017 | 94.52M |
| September 30, 2017 | 60.77M |
| June 30, 2017 | 6.335M |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | 15.00M |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | 19.77M |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | 0.73M |
| September 30, 2013 | 0.729M |
| June 30, 2013 | 0.73M |
| March 31, 2013 | 0.73M |
| December 31, 2012 | 21.95M |
| September 30, 2012 | 9.357M |
| June 30, 2012 | 10.57M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
236.60M
Minimum
Mar 2021
622.10M
Maximum
Sep 2024
376.34M
Average
345.10M
Median
Revenue (Quarterly) Benchmarks
| Repligen Corp | 154.87M |
| West Pharmaceutical Services Inc | 746.90M |
| Bruker Corp | 864.40M |
| The Cooper Companies Inc | 1.003B |
| Integra Lifesciences Holdings Corp | 380.83M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 129.80M |
| Total Expenses (Quarterly) | 437.30M |
| EPS Diluted (Quarterly) | 1.24 |
| Enterprise Value | 11.43B |
| Gross Profit Margin (Quarterly) | 98.71% |
| Profit Margin (Quarterly) | 20.86% |
| Earnings Yield | 2.98% |
| Operating Earnings Yield | 4.55% |
| Normalized Earnings Yield | 2.531 |